On 1 November 2024, revised diagnostic criteria for Alzheimer's disease were presented on behalf of the International Working Group (IWG) during the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The IWG, which includes Alzheimer Europe, reviewed the available evidence on the role and influence of biomarkers on the diagnosis and definition of AD, proposing a number of recommendations, which were published in the journal JAMA Neurology, in parallel to CTAD.
We are pleased to share the professional photographs from the 34th Alzheimer Europe Conference (#34AEC), as well as the videos of the plenary presentations from the event, all of which have now been published online.
On 14 November, following a re-examination of its initial opinion, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency issued a positive opinion on the marketing authorisation application for lecanemab for the treatment of early Alzheimer’s disease. The CHMP found that the benefits for a restricted population outweighed the risks. We welcome the news, which will enable patients to make informed decisions for themselves.
We continue to make great headway in our work engaging with MEPs and working with them to prioritise dementia at a European level. Three more MEPs have joined the European Alzheimer’s Alliance this month, bringing the total to 79 members!
Alzheimer Europe's 
On 1 November 2024, revised diagnostic criteria for Alzheimer's disease were presented on behalf of the International Working Group (IWG) during the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference. The IWG, which includes Alzheimer Europe, reviewed the available evidence on the role and influence of biomarkers on the diagnosis and definition of AD, proposing a number of recommendations, which were published in the journal JAMA Neurology, in parallel to CTAD.
We are pleased to share the professional photographs from the 34th Alzheimer Europe Conference (#34AEC), as well as the videos of the plenary presentations from the event, all of which have now been published online. 
On 14 November, following a re-examination of its initial opinion, the Committee for Medicinal Products for Human use (CHMP) of the European Medicines Agency issued a positive opinion on the marketing authorisation application for lecanemab for the treatment of early Alzheimer’s disease. The CHMP found that the benefits for a restricted population outweighed the risks. We welcome the news, which will enable patients to make informed decisions for themselves.
